Latest Commercial Sales News

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

Volt Group’s first quarter of FY26 saw ordinary revenue receipts surge 150% year-on-year to $3 million, driven by the integration of 4D Delta and strong contributions from its subsidiaries Wescone and EcoQuip.

Green360 Technologies has produced its first commercial batch of Eco-Clay under a tolling deal with Calix, advancing its low-carbon cement alternative towards market entry in Victoria by mid-2026.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Aguia Resources’ Brazilian subsidiary has achieved a key regulatory milestone with official fertiliser registration, enabling commercial sales of its PAMPAFOS phosphate product in Brazil’s large agricultural market.

Syrah Resources has opened its retail entitlement offer to raise approximately A$104 million, supported by strategic funding proposals from US and Australian government-linked entities. The capital raise aims to underpin the ramp-up of its Balama graphite mine and Vidalia anode material facility.

GCM Corporation has launched its first Very High Density (VHD) heat sink product line, marking a pivotal step from development to commercial sales in thermal management technology.